HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:May 2013
Contact:Peter Ahn, MD
Email:PennCancerTrials@emergingmed.com
Phone:855-216-0098

Use our guide to learn which trials are right for you!

A Pilot, Single-Center Study Of Quantitative HPV Serum Or Plasma DNA As A Prognostic Marker In P16+/HPV+ Squamous Carcinomas Of The Oropharynx And Unknown Primary Head And Neck Cancers

To assess in an exploratory manner, the pronostic utility for locoregional control,
progression-free and distant metastasis-free survival of a pre-therapy and post-therapy
blood DNA test of HPV E6 and E7 DNA for subtypes 16 and 18 in p16+ and/or HPV+ oropharyngeal
cancer patients. This will entail analysis of both initial pre-therapy HPV level as a
continuous variable and initial post-therapy HPV level as a dichotomous variable.


Inclusion Criteria:

- Histoloically proven primary cancer of the oropharynx, p16(+) and/or HPV (+), who are
planned for treatment with resection, radiation and/or chemotherapy.

- Subsites of oropharynx:include tonsil, base of tongue, vallecula, oropharyngeal wall,
soft palate, glossotonsillar sulcus.

- No or minimal smoking history ( last 10 years based on documented history and/or subject report)

- Age 18 years or older

- Subjects are capable of giving informed consent or have an acceptabl;e surrogate
capable of giving consent on the subjects behalf.

- Enrollment on any other study, regardless of therapy is allowed.

- Enrollment on any other tumor or tissue banking study is allowed.

- Patients who have had blood drawn as part of another study, including the
IRB-approved ENT Tumor Bank Study, may be included in this study even if the patient
has already had surgery.

Exclusion Criteria:

- Previous chemotherapy or radiation therapy to the head and neck unrelated to current
disease.

- Previous surgery for head and neck cancer unrelated to current disease.

- Widespread , biopsy-proven metastatic disease (stage IVC disease) at time of
presentation (small indeterminate lung or mediastinal nodules are allowed)

- Patients who have started induction chemotherapy prior to consideration for study
eligibility.

- Another active cancer except nonmelanomatous skin cancer.

- History of cervical penile or anal cancer.

- Patient treated with surgery, adjuvant radiation therapy or chemotherapy outside of
the University of Pennsylvania.

- History of smoking in the past last 12 months 10 years

- History of 10 pack-years of cigarette smoking based on documented history and/or
subject report

- Presence of sidespread leukoplakia or erythroplakia.
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
(215) 662-6065
Principal Investigator: Peter Ahn, MD
Phone: 855-216-0098
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials